Description: PTACH (Cpd 51) (NCH-51) is a SAHA-based inhibitor of human HDAC. It can potently inhibit the growth of various human Y cells (EC50: 1 to 10 µM). Target: HIV Protease, HDAC. Smiles: N(C(CCCCCCSC(C(C)C)=O)=O)C1=NC(=CS1)C2=CC=CC=C2. References: Suzuki T, et al. J Med Chem. 2005 Feb 24,48(4):1019-32.

Synthetic. Chemical. CAS: 848354-66-5. Formula: C20H26N2O2S2. MW: 390.56. Synthetic. Potent non-hydroxamate HDAC inhibitor (HDACi) (IC50: 32, 48 and 41nM for HDAC4, HDAC1 and HDAC6, respectively). Cell-permeable prodrug that is intracellularly converted to the potent HDAC inhibitor NCH 31. Predicted to exhibit a...

White crystals. Soluble in DMSO (25mg/ml). Non-hydroxamate HDAC inhibitor (HDACi) (IC50: 32, 48 and 41nM for HDAC4, HDAC1 and HDAC6, respectively). Cell-permeable prodrug that is intracellularly converted to a potent HDAC inhibitor. Predicted to exhibit a similar HDAC binding mode as that of SAHA, interacting with...

NCH-51 is an inhibitor of histone deacetylases (HDACs) with IC50 values of 48, 32, and 41 nM for HDAC1, 4, and 6, respectively. It increases acetylation of histone H4 and alpha-tubulin in HCT116 cells when used at concentrations ranging from 1 to 25 µM and inhibits the growth of a variety of cancer cell lines (EC50s...